Refined heart rate cutoffs may improve prognostic value of acute PE scoring systems
September 21, 2021
In an observational registry-based study, dropping the 110-bpm heart rate threshold improved sensitivity for low-risk PE, while increasing it improved specificity for intermediate-high–risk PE.
Study gives bleeding risk estimates for VTE patients on anticoagulants
September 13, 2021
New research provides best available estimates of long-term bleeding risk with different anticoagulants, authors say.
Apixaban more effective, safer than rivaroxaban for Afib patients
August 23, 2021
Is apixaban more effective and safer than rivaroxaban in patients with atrial fibrillation?
Heparin’s COVID-19 benefit greatest in moderately ill patients
August 13, 2021
A multiplatform trial reported that therapeutic heparin improved outcomes in moderately ill COVID-19 patients but not in critically ill patients.
DOACs best aspirin after ventricular ablation: STROKE-VT
August 2, 2021
Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.
Direct oral anticoagulants: Competition brought no cost relief
July 27, 2021
Medicare Part D spending since 2011 has far outpaced growth in the use of oral anticoagulants.
Aspirin efficacious and safe for VTE prophylaxis in total hip and knee replacement
July 23, 2021
Is aspirin effective and safe for VTE prophylaxis in patients undergoing total hip and knee replacement?
DOACs linked to lower mortality than vitamin K antagonist: 3-year TAVR registry
July 16, 2021
Mortality and bleeding advantage favors DOACs over VKA in TAVR patients who are candidates for anticoagulation.
Early heparin treatment linked to lower COVID-19 mortality
July 15, 2021
Rates of death were significantly lower by almost half in patients who received early heparin than in those who did not.
Prophylactic anticoagulation tied to lower death rate in COVID
June 18, 2021
Prophylactic use of low-dose anticoagulation to prevent venous thromboembolism was associated with reduced 60-day mortality in patients hospitalized with COVID-19 in Michigan.